CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Physiological saline solutionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug2091 RhACE2 APN01 Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19

Recombinant human angotensin-converting enzyme 2 (rhACE2) as a treatment for patients with COVID-19 to block viral entry and decrease viral replication.

NCT04335136 COVID-19 Drug: RhACE2 APN01 Drug: Physiological saline solution

Primary Outcomes

Description: The primary endpoint is a composite endpoint of all cause-death or invasive mechanical ventilation up to 28 days or hospital discharge

Measure: All Cause-death or invasive mechanical ventilation

Time: 28 days

Secondary Outcomes

Description: Log transformed levels of Lactate dehydrogenase (LDH) at day 5 as a surrogate marker for organ damage (powered secondary endpoint

Measure: LDH level

Time: Day 5

Description: 28-day mortality (all cause-death)

Measure: Mortality

Time: 28 days

Description: Ventilator-free days (VFD) up to 28 days or hospital discharge

Measure: VFD

Time: 28 days

Description: Time to death (all causes)

Measure: Time to death

Time: 28 days


No related HPO nodes (Using clinical trials)